Open AccessEvidence for Expanding the Role of Streptomycin in the Management of Drug-Resistant Mycobacterium tuberculosis
Author(s) -
Keira A. Cohen,
Katharine E. Stott,
Vanisha Munsamy,
Abigail L. Manson,
Ashlee M. Earl,
Alexander S. Pym
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00860-20
Subject(s) - streptomycin , bedaquiline , mycobacterium tuberculosis , amikacin , tuberculosis , drug resistance , aminoglycoside , medicine , biology , microbiology and biotechnology , antibiotics , virology , pathology
In 2019, the WHO tuberculosis (TB) treatment guidelines were updated to recommend only limited use of streptomycin, in favor of newer agents or amikacin as the preferred aminoglycoside for drug-resistantMycobacterium tuberculosis . However, the emergence of resistance to newer drugs, such as bedaquiline, has prompted a reanalysis of antitubercular drugs in search of untapped potential. Using 211 clinical isolates ofM. tuberculosis from South Africa, we performed phenotypic drug susceptibility testing (DST) to aminoglycosides by both critical concentration and MIC determination in parallel with whole-genome sequencing to identify known genotypic resistance elements.